Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Host-informed molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine [Ribo-seq]

ABSTRACT: Host-informed molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine [Ribo-seq]

PROVIDER: PRJNA668384 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12804255_1.fastq.gz	Fastqsanger.gz
	SRR12804255_2.fastq.gz	Fastqsanger.gz
	SRR12804256_1.fastq.gz	Fastqsanger.gz
	SRR12804256_2.fastq.gz	Fastqsanger.gz
	SRR12804257_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 14

Similar Datasets

Host-informed molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine

Project description:Host-informed molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine

| PRJNA668385 | ENA

Host-informed molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine [RNA-seq]

Project description:Host-informed molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine [RNA-seq]

| PRJNA668364 | ENA

Host-informed molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine [Ribo-seq]

Project description:We analyzed total RNA and ribosome footprints collected from a K. phaffii strain secreting the VP8-P[6] serotype of the rotavirus antigen and compared against a strain secreting the VP8-P[4] serotype for reference.

2021-05-05 | GSE159336 | GEO

Host-informed molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-05-05 | GSE159338 | GEO

Host-informed molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine [RNA-seq]

Project description:We analyzed the transcriptomes of K. phaffii strains secreting the VP8-P[6] serotype of the rotavirus antigen, and compared against null strains as well as strains secreting the VP8-P[4] or VP8-P[8] serotype in order to diagnose bottlenecks limiting robust secretion of P[6].

2021-05-05 | GSE159325 | GEO

Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirus.

Project description:BackgroundVaccines comprising recombinant subunit proteins are well-suited to low-cost and high-volume production for global use. The design of manufacturing processes to produce subunit vaccines depends, however, on the inherent biophysical traits presented by an individual antigen of interest. New candidate antigens typically require developing custom processes for each one and may require unique steps to ensure sufficient yields without product-related variants.ResultsWe describe a holistic approach for the molecular design of recombinant protein antigens-considering both their manufacturability and antigenicity-informed by bioinformatic analyses such as RNA-seq, ribosome profiling, and sequence-based prediction tools. We demonstrate this approach by engineering the product sequences of a trivalent non-replicating rotavirus vaccine (NRRV) candidate to improve titers and mitigate product variants caused by N-terminal truncation, hypermannosylation, and aggregation. The three engineered NRRV antigens retained their original antigenicity and immunogenicity, while their improved manufacturability enabled concomitant production and purification of all three serotypes in a single, end-to-end perfusion-based process using the biotechnical yeast Komagataella phaffii.ConclusionsThis study demonstrates that molecular engineering of subunit antigens using advanced genomic methods can facilitate their manufacturing in continuous production. Such capabilities have potential to lower the cost and volumetric requirements in manufacturing vaccines based on recombinant protein subunits.

| S-EPMC8088319 | biostudies-literature

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer ImmunotherapyRepurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy

Project description:In this study, we show that intratumoral injections of the trivalent measles, mumps, and rubella (MMR) live attenuated viral vaccine (LAVs) modulate a potent cytotoxic T cells immune response, resulting in tumor growth inhibition and improved survival in syngeneic mouse models of hepatocellular carcinoma (HCC) and colorectal cancer (CRC).

2022-10-27 | PXD031295 | Pride

Systems biology of immunity to MF59-adjuvanted versus non-adjuvanted trivalent seasonal influenza vaccines in early childhood

Project description:Here we applied systems approaches to investigate the innate and adaptive responses to trivalent inactivated influenza vaccine (TIV) and MF59-adjuvanted TIV (ATIV) in ninety 14-24 month old healthy children.

2016-01-31 | GSE74975 | GEO

Time series of global gene expression after trivalent influenza vaccination in humans (female cohort)

Project description:The purpose of the study was to assess the patterns of global gene expression in peripheral blood cells before and at three time points after the administration of a trivalent influenza vaccine in human female subjects, and to relate these to the antibody response to the vaccine

2013-06-18 | GSE48023 | GEO

A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells

Project description:The manufacturing of autologous chimaeric antigen receptor (CAR) T cells largely relies either on fed-batch and manual processes that often lack environmental monitoring and control or on bioreactors that cannot be easily scaled out to meet patient demands. Here we show that human primary T cells can be activated, transduced and expanded to high densities in a 2 ml automated closed-system microfluidic bioreactor to produce viable anti-CD19 CAR T cells (specifically, more than 60 million CAR T cells from donor cells derived from patients with lymphoma and more than 200 million CAR T cells from healthy donors). The in vitro secretion of cytokines, the short-term cytotoxic activity and the long-term persistence and proliferation of the cell products, as well as their in vivo anti-leukaemic activity, were comparable to those of T cells produced in a gas-permeable well. The manufacturing-process intensification enabled by the miniaturized perfusable bioreactor may facilitate the analysis of the growth and metabolic states of CAR T cells during ex vivo culture, the high-throughput optimization of cell-manufacturing processes and the scale-out of cell-therapy manufacturing.

2024-05-29 | GSE261103 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data